[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ocular Therapeut (OCUL)

Ocular Therapeut (OCUL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,112,964
  • Shares Outstanding, K 218,960
  • Annual Sales, $ 51,950 K
  • Annual Income, $ -265,940 K
  • EBIT $ -270 M
  • EBITDA $ -266 M
  • 60-Month Beta 0.93
  • Price/Sales 40.80
  • Price/Cash Flow N/A
  • Price/Book 3.64

Options Overview Details

View History
  • Implied Volatility 83.38% (+6.66%)
  • Historical Volatility 66.29%
  • IV Percentile 50%
  • IV Rank 11.79%
  • IV High 363.10% on 02/13/26
  • IV Low 46.01% on 08/22/25
  • Expected Move (DTE 3) 0.52 (5.59%)
  • Put/Call Vol Ratio 0.27
  • Today's Volume 1,564
  • Volume Avg (30-Day) 1,446
  • Put/Call OI Ratio 0.21
  • Today's Open Interest 44,913
  • Open Int (30-Day) 55,352
  • Expected Range 8.76 to 9.80

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.40
  • Number of Estimates 5
  • High Estimate $-0.36
  • Low Estimate $-0.42
  • Prior Year $-0.39
  • Growth Rate Est. (year over year) -2.56%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.64 +7.47%
on 04/14/26
9.98 -6.97%
on 05/06/26
+0.49 (+5.57%)
since 04/10/26
3-Month
6.23 +48.95%
on 02/17/26
11.50 -19.30%
on 03/03/26
+0.12 (+1.31%)
since 02/11/26
52-Week
6.23 +48.95%
on 02/17/26
16.44 -43.55%
on 12/08/25
+2.22 (+31.44%)
since 05/09/25

Most Recent Stories

More News
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BEDFORD, Mass., May 08, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina...

OCUL : 9.28 (-3.83%)
Why Ocular Therapeutix (OCUL) Stock Is Nosediving

Why Ocular Therapeutix (OCUL) Stock Is Nosediving

OCUL : 9.28 (-3.83%)
Ocular Therapeutix (NASDAQ:OCUL) Reports Sales Below Analyst Estimates In Q1 CY2026 Earnings

Ocular Therapeutix (NASDAQ:OCUL) Reports Sales Below Analyst Estimates In Q1 CY2026 Earnings

OCUL : 9.28 (-3.83%)
Ocular Therapeutix: Q1 Earnings Snapshot

Ocular Therapeutix: Q1 Earnings Snapshot

OCUL : 9.28 (-3.83%)
Ocular Therapeutix™ Reports First Quarter 2026 Financial Results and Business Highlights

Enrollment underway in SOL-X long-term extension trial in wet AMD for subjects completing two-year follow-up in SOL-1 or SOL-R Announced positive Phase 3 SOL-1 results in February 2026, first ever...

OCUL : 9.28 (-3.83%)
Ocular Therapeutix Reports as SOL-1 Trial Data Shifts From Presentation to Implementation

Barchart Research What to Expect from OCUL Earnings OCUL Generated May 4, 2026 Current Price $9.77 EPS Estimate $$-0.32 Consensus Rating Strong Buy Average Move 6.93% Ocular Therapeutix Reports as SOL-1...

OCUL : 9.28 (-3.83%)
Ocular Therapeutix (OCUL) To Report Earnings Tomorrow: Here Is What To Expect

Ocular Therapeutix (OCUL) To Report Earnings Tomorrow: Here Is What To Expect

OCUL : 9.28 (-3.83%)
Ocular Therapeutix™ Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI™ in Wet AMD

SOL-X long-term extension trial in wet AMD enrolled the first subject in April 2026 who had successfully completed the two-year SOL-1 trial  Subjects who have completed the two-year follow-up in...

OCUL : 9.28 (-3.83%)
Ocular Therapeutix™ to Report First Quarter 2026 Financial Results on May 5, 2026

BEDFORD, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today...

OCUL : 9.28 (-3.83%)
Ocular Therapeutix™ to Participate in May Scientific and Investor Conferences

BEDFORD, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today...

OCUL : 9.28 (-3.83%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Ocular Therapeutix, Inc. is a biopharmaceutical company. It is focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. The Company develops and markets eye care products. Ocular...

See More

Key Turning Points

3rd Resistance Point 10.16
2nd Resistance Point 9.95
1st Resistance Point 9.61
Last Price 9.28
1st Support Level 9.06
2nd Support Level 8.85
3rd Support Level 8.51

See More

52-Week High 16.44
Fibonacci 61.8% 12.54
Fibonacci 50% 11.34
Fibonacci 38.2% 10.13
Last Price 9.28
52-Week Low 6.23

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.